China Resources Pharmaceutical Group Limited - B (02171) expects a decrease in both mid-term net loss and net loss adjusted for the same period compared to the previous year.

Zhitong Finance APP News, Keji Pharmaceutical-B (02171) announced that, based on the preliminary evaluation of the latest unaudited management accounts of the Group for the six months ended June 30, 2025 (the reporting period) and the information currently available to the Board of Directors, and based on a series of factors including the commercialization of CT053 and the acceptance of the new drug application (NDA) for CT041 by the National Medical Products Administration (NMPA), it is expected that the Group will incur a net loss and a decrease in adjusted net loss compared to the same period last year.